Drug Discovery

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology

Toxicogenomics – Insights into the present and future

By Dr Patrick J. Vojta, Vincent P. Kazmer and Dr Larry D. Kier Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1). This article… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Gene therapy #Genomics #High Content Screening #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology

Metabolism Provides Alternative Door to Stroke Therapy

Metabolism Provides Alternative Door to Stroke Therapy By Dr Keith F. Martin and Tony Dolan Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs. You know that feeling you get the day after an exaggerated attempt at physical… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Biochemistry #Cellular & Molecular biology #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High throughput screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Proteomics In Drug Target Discovery – High-throughput meets high-efficiency

Proteomics In Drug Target Discovery - High-throughput meets high-efficiency By Dr Terence E. Ryan and Dr Scott D. Patterson Biochemistry is enjoying a renaissance under the guise of 'proteomics' due to the availability of sequenced genomes, advances in mass spectrometry and associated data analysis. Its application to drug discovery and… Read More

#Archive

#Academic #ADME / Tox #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Organic chemistry #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Cell Based Assays – Seeing the light

Cell Based Assays - Seeing the light By Dr Nick Thomas High-context cell assays have the potential to take the pivotal role in the drug discovery process. So what are the features of today's leading edge cell based assay technologies and where does the future lie? We live in interesting… Read More

#Archive

#AI / data analytics / healthtech / informatics #Assay development & optimisation #Automation / robotics #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Microbiology #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Pharmokinetics #Precision medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Silicon Technology and Pharmaceutics

Silicon Technology and Pharmaceutics by Professor Leigh T. Canham, Dr Roghieh S. Saffie, Stephen E. Connor and Dr Roger Aston The recent discovery that, following nanostructuring, silicon can be rendered biocompatible and biodegradable has far reaching and profound long-term implications for the pharmaceutical industry and, indeed, medicine as a whole. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Therapeutics

A Revolution in R&D – The managerial challenges

The genomics revolution is poised to sweep aside the old economics of pharmaceutical R&D. The biotechnology and pharmaceutical industries; and perhaps healthcare delivery in general; are on the brink of transformation, and companies that embrace the revolution in the right way stand to reap enormous benefits. Developing a new drug… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Protein chemistry / Proteomics #RNA #Screening #Stem cells

Hit to lead and lead to candidate optimisation using multi-parametric principles

Hit to lead and lead to candidate optimisation using multi-parametric principles By Dr Anthony D. Baxter and Dr Peter M. Lockey As the numbers of potential target proteins become available for pharmaceutical companies of all sizes, the drive towards more cost-effective drug discovery assumes greater significance. It is a truism… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Genomics #High Content Screening #High throughput screening #Lead discovery #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation

Data Mining in the pharmaceutical industry

Data Mining in the pharmaceutical industry By Dr Robert D. Small and Herbert A. Edelstein A research-based pharmaceutical company is a data accumulating wonder. More than in any other industry, success is predicated on the collection, processing and exploitation of that data. This is not always recognised and often not… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Cell culture #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #Therapeutics #Toxicology

Evaluating future drug candidates and their manufacture together

Evaluating future drug candidates and their manufacture together By Professor Peter Dunnill Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology

Chemogenomics – A gene family approach to parallel drug discovery

Chemogenomics - A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent reports from efforts… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Microfluidics #Patent Law #PCR #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening

The lab on a chip and its impact on drug discovery

The lab on a chip and its impact on drug discovery by Dr Simon Cowen and Dr Coulton Legge Few technology developments have had as profound an effect on society as the invention of the microchip integrated circuit in the 1960s. Since then, the power of electronic circuits has increased… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Business #Drug development #Drug discovery #High Content Screening #Lead discovery #RNA

Why pharmaceutical companies should teach scientists to be entrepreneurs

Why pharmaceutical companies should teach scientists to be entrepreneurs By Dr Jeffrey P. Kiplinger Conventional wisdom says that big employers do not want anything to do with entrepreneurs as employees. The last thing a human resources director wants to see on a resume is that a candidate started a business… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation

The Impact of Genomics on Regulation

The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far… Read More

#Archive

#Analysis #Animal models #Automation / robotics #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics #Toxicology

New Developments in Analgesia

New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Cell therapy #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Lead discovery #Regulatory #RNA

Health economic considerations for early drug discovery

Health economic considerations for early drug discovery By Dr Ann-Marie Craig and Dr Lisa Kennedy The use of health economics in early phase development, while not an exact science, can, when conjoined with clinical evidence, be a very valuable information tool enabling companies to identify whether there is a market… Read More

#Archive

#Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Toxicology

Surrogate Endpoints In Cancer Trials

Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More

#Archive